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The lantibiotic haloduracin consists of two post-
translationally processed peptides, Hala and Halb,
which act in synergy to provide bactericidal activity.
An in vitro haloduracin production system was used
to examine the biological impact of disrupting indi-
vidual thioether rings in each peptide. Surprisingly,
the Hala B ring, which contains a highly conserved
CTLTXEC motif, was expendable. This motif has
been proposed to interact with haloduracin’s pre-
dicted target, lipid II. Exchange of the glutamate
residue in this motif for alanine or glutamine com-
pletely abolished antibacterial activity. This study
also established that Hala-Ser26 and Halb-Ser22
escape dehydration, requiring revision of the Halb
structure previously proposed. Extracellular prote-
ases secreted by the producer strain can remove
the leader peptide, and the Hala cystine that is dis-
pensable for bioactivity protects Hala from further
proteolytic degradation.
INTRODUCTION
Lantibiotics are a class of cyclic peptides produced by Gram-
positive bacteria. They are ribosomally synthesized as inactive
precursor peptides that undergo posttranslational modification
to generate their mature, biologically active forms. More than
50 lantibiotics are known to date, most of which function as anti-
microbial peptides (Chatterjee et al., 2005b; Cotter et al., 2005;
Willey and van der Donk, 2007). Notably, the most extensively
studied member, nisin, has been used worldwide for decades
in the food industry without the development of widespread
antibiotic resistance (Delves-Broughton et al., 1996). Moreover,
other lantibiotics, such as mersacidin, lacticin 3147, and micro-
bisporicin, are effective against methicillin-resistant Staphylo-
coccus aureus and other multidrug-resistant pathogens (Casti-
glione et al., 2008; Galvin et al., 1999; Kruszewska et al., 2004).
All lantibiotics contain the characteristic lanthionine (Lan) and/
or methyllanthionine residues (MeLan), and also typically the
unsaturated amino acids dehydroalanine (Dha) and dehydrobu-
tyrine (Dhb) that are introduced by posttranslational modifica-
tion. Lantibiotic precursor peptides (LanA) consist of a structuralChemistry & Biology 15, 1035–region that will be transformed into the antimicrobial peptide and
an N-terminal leader sequence that does not undergo modifica-
tion. Specific Ser and Thr residues in the structural region are
enzymatically dehydrated to yield Dha and Dhb, respectively
(Figure 1). Through a Michael-type addition, Cys residues react
with these dehydro amino acids to form the thioether rings,
Lan fromSer andMeLan from Thr. The precise roles of the leader
peptide are still under debate (Furgerson Ihnken et al., 2008;
Levengood et al., 2007; Patton et al., 2008), but following modi-
fication it must be removed by proteolysis to generate the active
lantibiotic (Chen et al., 2001; Corvey et al., 2003; Li et al., 2006;
McClerren et al., 2006; van der Meer et al., 1994; Xie et al., 2004).
A subclass of lantibiotics consists of the two-peptide systems.
These compounds are formed from two precursor peptides
posttranslationally modified to create two distinct products
that act in synergy to provide bactericidal activity (Garneau
et al., 2002). Currently, seven two-component lantibiotics are
known, including the best-studied example, lacticin 3147
(Ryan et al., 1999), and the most recently identified member,
haloduracin (Lawton et al., 2007; McClerren et al., 2006). For hal-
oduracin, produced by the Gram-positive alkaliphilic bacterium
Bacillus halodurans C-125, the unmodified peptides HalA1 and
HalA2 are each dehydrated and cyclized by two dedicated
bifunctional enzymes, HalM1 and HalM2, respectively. During
this process, one of the four Ser/Thr residues in the structural
region of HalA1 and one of the eight Ser/Thr residues in the struc-
tural peptide of HalA2 escape dehydration by their respective
modification enzymes. Proteolytic removal of the leader peptide
results in the mature, active components, Hala and Halb. The
HalA1 peptide is predicted to have 32% and 44% amino acid se-
quence identity with the precursor peptides from mersacidin
(P43683) and lacticin 3147 A1 (O87236), respectively. Both mer-
sacidin and the mature A1 component of lacticin 3147 bind to
lipid II, an essential precursor in peptidoglycan biosynthesis
(Bro¨tz et al., 1998; Wiedemann et al., 2006). A sequential model
has been proposed for the bactericidal action of two-peptide
lantibiotics in which the a (A1) peptide first binds to lipid II and
the a:lipid II complex serves as a docking site for the b (A2) pep-
tide. Once recruited, the extended conformation of the b compo-
nent is believed to facilitate pore formation in the bacterial mem-
brane (Morgan et al., 2005; Wiedemann et al., 2006).
Herein, the structural features essential for biological activity
of haloduracin were investigated using a recently developed
in vitro biosynthetic system (McClerren et al., 2006). A number
of haloduracin analogs were constructed and the impact of the1045, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1035
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SAR Studies of the Lantibiotic Haloduracinalterations on antibiotic activity was assessed. In addition, this
study suggests that some or all of the proteolytic process that
removes the leader peptides may be performed by extracellular
proteases secreted by the B. halodurans producing strain.
RESULTS
Structures of Hala and Halb
Based on the mass of haloduracin prepared enzymatically
in vitro as well as the products isolated from B. halodurans
C-125, one Ser/Thr residue escapes dehydration in both Hala
and Halb (McClerren et al., 2006). To identify the locations of
these residues and to examine their biological significance, spe-
cific Ser/Thr residues were mutated in the substrate peptides to
Ala. The mutant substrates were subjected to HalM1 or HalM2
and analyzed by MALDI-TOF MS. For HalA1, three of four resi-
Figure 1. General Overview of the Common Steps in Lantibiotic
Biosynthesis
LanA, lantibiotic precursor peptide.1036 Chemistry & Biology 15, 1035–1045, October 20, 2008 ª2008dues undergo dehydration. Comparison of its sequence to that
of other lantibiotics suggested that Ser26 escaped dehydration
(McClerren et al., 2006; Figure 2A). To test this hypothesis the
S26A mutant of HalA1-Xa was constructed by site-directed
mutagenesis and processed in vitro with HalM1. As discussed
previously (McClerren et al., 2006), this substrate contains a
Factor Xa recognition site for leader peptide removal. Upon sub-
jection to HalM1 under standard assay conditions (McClerren
et al., 2006), three dehydrations were still observed by MS (see
Figure S1A available online), thus indicating that Ser26 is indeed
the residue that is not acted upon by HalM1. For Halb, it was es-
tablished that seven of eight Ser/Thr residues undergo dehydra-
tion in the structural region of HalA2 (McClerren et al., 2006).
Based on homology to other lantibiotics it was proposed that
Thr18 was not dehydrated. However, when the T18A mutant of
HalA2-Xa was treated with HalM2, a product with 6-fold dehy-
dration was observed (Figure S1B). This finding strongly sug-
gests that Thr18 is normally dehydrated by HalM2. FTMS/MS
data obtained previously narrowed down the other possible
candidates for the residue that is not dehydrated to Thr17,
Thr21, or Ser22 (McClerren et al., 2006). Thr17 and Thr21 are
believed to be involved in methyllanthionine rings that are highly
conserved in two-component lantibiotics (McClerren et al.,
2006). Thus, HalA2-Xa S22A was constructed and subjected to
HalM2 catalysis. MS analysis showed that this mutant was dehy-
drated 7-fold (Figure 3), demonstrating that Ser22 escapes
dehydration by HalM2 in wild-type HalA2. The structure for
Halb has been revised to reflect these data (Figure 2B).
The cyclization reaction is more difficult to examine because it
does not involve a change in mass. In previous studies, tech-
niques were developed that report on noncyclized cysteines
through derivatization of their thiol groups (Li and van der
Donk, 2007; Li et al., 2006; McClerren et al., 2006; Paul et al.,
2007). Control reactions with unmodified HalA1 and HalA2 sub-
strates indicated that iodoacetamide (IAA) wasmore effective for
HalA1, whereas p-hydroxymercuribenzoic acid (PHMB) (Li and
van der Donk, 2007; Paul et al., 2007; Pitts and Summers,
2002) showed better derivatization efficiency for HalA2. Hence,
throughout this study IAA was used to test cyclization of HalA1
mutants, and PHMB was used for HalA2. The reasons behind
the different derivatization efficiency of these peptides were
not investigated but are likely related to their different solubilities.
The products of the enzyme assays with HalA1-Xa S26A, HalA2-
Xa T18A, and HalA2-Xa S22A were treated with reductant fol-
lowed by thiol derivatizing agent and monitored by MALDI-TOF
MS, showing that none of the assay products displayed adducts
(beyond the two expected for the cysteine residues of the disul-
fide in Hala) and demonstrating that thesemutants were cyclized
(Figure S1C–E). Removal of the leader peptide for evaluation of
antimicrobial activity of the haloduracin analogs produced was
accomplished using the previously described Factor Xa engi-
neered system (McClerren et al., 2006). Briefly, in substrates
denoted HalA1/2-Xa, the four amino acids in the leader peptides
immediately prior to the structural region of HalA1 (Val-Asn-Gly-
Ala) and HalA2 (Val-His-Ala-Gln) were replaced with the Factor
Xa recognition site (Ile-Glu-Gly-Arg; Figure 2). After treatment
of the HalM1 and HalM2 enzymatic products with Factor Xa
and confirmation of proteolytic processing by MALDI-TOF MS,
agar diffusion assays against a haloduracin-sensitive strain,Elsevier Ltd All rights reserved
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showed that the two residues that escape dehydration (Hala
Ser26 and Halb Ser22) are not necessary for antibacterial activity
as replacement with Ala still resulted in zones of growth inhibi-
tion. Furthermore, when an Ala residue was installed in place
of Dhb18 of Halb, bioactivity was retained (Figure 4, regions
14–16).
Thioether Ring Disruption in Hala and Halb
To evaluate the significance of each sulfide ring in Hala and Halb,
they were disrupted individually by converting Cys residues to
Ala in the substrate peptides. Previously it was shown that the
cystine linkage in Hala was not required for bacterial growth in-
hibition (McClerren et al., 2006). Even when the Cys thiols were
alkylated by treatment with iodoacetamide (IAA), a zone of inhi-
bition was observed in agar diffusion assays. The nonessential
nature of the cystine was confirmed in this study by generation
of the HalA1-Xa C8A peptide and incubation with HalM1, result-
ing in a 3-fold dehydrated product (Figure 5A). Subsequent anal-
ysis with IAA for cyclization as discussed previously showed that
themutant contained a single reactive Cys (Cys1), indicating that
three Cys residues were unavailable for alkylation (Figure 5B),
a result consistent with formation of three thioether rings. The
HalM1 product was treated with Factor Xa protease to remove
Figure 2. Biosynthesis of Hala and Halb
(A and B) In substrates designated HalA1-Xa or
HalA2-Xa, the four amino acids at positions 1
to 4 were replaced by IEGR (boxed in blue). In
(B), the revised structure of Halb is shown based
on the results in this study.
the leader sequence, and tested against
the bacterial indicator strain, resulting in
a zone of inhibition (Figure 4, region 3)
and confirming that the disulfide is dis-
pensable.
Using a similar strategy, the A, B, and C
rings were disrupted by mutating Cys17,
Cys23, and Cys27 of HalA1-Xa to Ala,
respectively. MALDI-TOF MS analysis of
the assay products prepared by incuba-
tion of the HalA1-Xa Cys-to-Ala mutants
with HalM1 showed that 3-fold dehydra-
tion occurred for all (Figure S2), and
IAA analysis revealed that all of these
HalM1-processed mutants contained
two reactive Cys residues corresponding
to Cys1 and Cys8. The IAA derivatization
studies suggest that all other Cys resi-
dues underwent the anticipated cycliza-
tion in these mutants. Subsequent re-
moval of the leader peptide and
qualitative antimicrobial assays showed
that the C ring was essential for bioactiv-
ity because the C27A mutant did not pro-
duce a zone of inhibition (Figure 4, region
6). Surprisingly, the B ring proved to be
expendable as Hala-C23A gave a clear inhibition zone when an-
tibiotic activity was assessed in three independent experiments
(Figure 4, region 5). A small but reproducible zone was observed
for the C17A mutant, suggesting the A ring is important but not
absolutely essential (region 4).
Evaluation of the importance of the Lan and MeLan rings in
Halb was similarly completed. The A, B, C, and D rings were in-
dividually disrupted by conversion of Cys5, Cys15, Cys20, and
Cys24 of HalA2-Xa to Ala, respectively. Incubation with HalM2
and analysis by MALDI-TOF MS revealed seven dehydrations
for all four mutants as shown for the C5A mutant in Figure 5C
(for all other mutants, see Figure S3). Subsequent analysis
with PHMB for cyclization showed that the mutants C5A,
C20A, and C24A did not contain any free thiols, suggesting
they underwent complete cyclization as shown for C5A in
Figure 5D (for other mutants, see Figure S3). However, C15A
did display multiple adducts derived from PHMB (Figure S3C),
indicating that disruption of the B ring also affected ring forma-
tion of one or more of the other rings. The consequences of re-
moval of one or more rings on antimicrobial activity were evalu-
ated by agar diffusion assays after leader peptide removal. The
mutant that lacked the A ring (C5A) retained antibiotic activity
(Figure 4, region 8). No zone of inhibition was observed for the
C15A mutant of Halb, and only weak zones of growth inhibitionChemistry & Biology 15, 1035–1045, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1037
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regions 9–11).
A Highly Conserved Glutamate Residue in Hala
Is Essential for Bioactivity
It was recently shown that a highly conserved glutamate in mer-
sacidin (Glu17) was essential for binding to its target lipid II (Bro¨tz
et al., 1998; Hsu et al., 2003; Szekat et al., 2003). Because of the
high degree of homology between the C ring of mersacidin and
the B ring of Hala (Figure 6A), the corresponding Glu22 could
play a similar role in themode of action of haloduracin. Therefore,
Glu22 in HalA1-Xa was mutated to Ala and Gln. Upon treatment
with HalM1, these mutants underwent three dehydrations as
expected (Figure 6B). Cyclization was confirmed using IAA
treatment under reducing conditions followed by MS analysis.
The two IAA adducts observed were assigned to the two Cys
residues that form the disulfide ring of HalA1-Xa (Figure 6C). Bio-
activity analysis after removal of the leader peptide with Factor
Xa showed that antibacterial activity was completely abolished
under the conditions used (Figure 4, regions 12 and 13).
Proteolytic Processing
Leader peptide removal for HalA1 and HalA2 is proposed to be
achieved in vivo by a single enzyme termed HalT (Lawton et al.,
2007; McClerren et al., 2006). The predicted cleavage site for
LanT protease domains is after a double-Gly recognition motif
(GG, GA, or GS sequences; Ha˚varstein et al., 1995; Nes and
Tagg, 1996). For HalA1, proteolysis behind the predicted cleav-
age site Gly-2Ala-1 (Figure 2A) was confirmed by mass spec-
trometry on haloduracin a produced by B. halodurans C-125
(McClerren et al., 2006). For HalA2, the cleavage was predicted
Figure 3. MALDI-TOF MS of HalA2-Xa S22A
HalA2-Xa S22A before (dashed line) and after
(solid line) incubation with HalM2. The asterisks
(*) indicate a phosphorylated peptide (Chatterjee
et al., 2005a).
to take place after Gly-8Ser-7 (Figure 2B),
yet the mass spectrometric data on Halb
produced by B. halodurans C-125
showed that residues Gly-6 through
Gln-1 were also removed (Figure 2B).
Therefore, if HalT cleaves after the GlySer
sequence, then an additional N-terminal
proteolytic step must occur. The biologi-
cal significance of the removal of the
residues GDVHAQ was examined by the
generation of a mutant of HalA2, desig-
nated HalA2-XaGS, with the Factor Xa
cleavage signal immediately following
the predicted HalT cleavage signal at
Gly-8Ser-7 (Figure S4A). This construct
was incubated with HalM2 to yield the
expected 7-fold dehydrated product (Fig-
ure S4B) and was further processed by
treatment with Factor Xa. When the re-
sulting product designated GDVHAQ-
Halb was tested for antibiotic activity in the presence of Hala,
inhibition zones comparable to in vivo and in vitro prepared
haloduracin were observed (Figure S4D). This data indicated
that the additional six amino acids on the N terminus of this mu-
tant product do not interfere with the bioactivity of haloduracin.
We investigated the possibility that N-terminal trimming of the
GDVHAQ-Halb product occurred on the agar plate by extracellu-
lar proteases from the reporter strain during the bioassay, and
that the trimmed Halb product was actually responsible for the
observed zone of inhibition. Furthermore, we investigated
whether the producer strain B. halodurans C-125 secretes a
protease that could perform N-terminal trimming of longer Halb
products. For this purpose, the HalA2-XaGS Q23A mutant was
generated. The Q23Amutation was introduced so that Halb gen-
erated by processing of GDVHAQ-Halb could be distinguished
from Halb produced endogenously by B. halodurans C-125.
This mutation was chosen because an Ala is present at this
position in lacticin 3147 A2. The peptide was expressed in
E. coli, purified, and subjected to HalM2 modification, resulting
in seven dehydrations and complete cyclization (Figures S5A
and S5B). Subsequent Factor Xa cleavage yielded GDVHAQ-
Halb Q23A as observed by MALDI-TOF MS. Incubation with
the L. lactis CNRZ 117 indicator strain did not result in process-
ing of GDVHAQ-HalbQ23A (Figure 7A). However, the culture su-
pernatant from the B. halodurans C-125 producer strain did con-
tain one or more proteases that cleanly removed the GDVHAQ
sequence, resulting in HalbQ23A (Figure 7A). In a second exper-
iment, full-length HalA2-XaGS Q23A processed by HalM2 was
incubated with the culture supernatant. Once more, proteolytic
processing occurred, removing the entire leader sequence and
producing Halb Q23A (Figure 7B). To examine the fate of Hala1038 Chemistry & Biology 15, 1035–1045, October 20, 2008 ª2008 Elsevier Ltd All rights reserved
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SAR Studies of the Lantibiotic HaloduracinFigure 4. Antimicrobial Activity Assays for Haloduracin Mutants against the Indicator Strain L. lactis CNRZ 117
In vitro refers to compound produced with purified HalM enzymes and subsequent proteolysis with Factor Xa. In vivo refers to Hala or Halb isolated and purified
fromB. haloduransC-125. Region 1, Hala + Halb (both in vivo); region 2, Hala (in vitro) and Halb (in vivo); region 3, HalaC8A (in vitro) + Halb (in vivo); region 4, Hala
C17A (in vitro) + Halb (in vivo); region 5, Hala C23A (in vitro) + Halb (in vivo); region 6, Hala C27A (in vitro) + Halb (in vivo); region 7, Hala (in vivo) + Halb (in vitro);
region 8, Hala (in vivo) + Halb C5A (in vitro); region 9, Hala (in vivo) + Halb C15A (in vitro); region 10, Hala (in vivo) + Halb C20A (in vitro); region 11, Hala (in vivo) +
Halb C24A (in vitro); region 12, Hala E22A (in vitro) + Halb (in vivo); region 13, Hala E22Q (in vitro) + Halb (in vivo); region 14, Hala S26A (in vitro) + Halb (in vivo);
region 15, Hala (in vivo) + Halb Dhb18Ala (in vitro); region 16, Hala (in vivo) + Halb S22A (in vitro).under these conditions, purified Hala was incubated with the
culture supernatant of B. halodurans C-125 with and without
pretreatment with the reductant tris(2-carboxyethyl)phosphine
(TCEP) to reduce the N-terminal disulfide and subsequent
alkylation by IAA. Interestingly, the Hala that was not treated
with TCEP/IAA did not undergo any proteolysis as judged by
MALDI-TOF MS (Figure S5D), but the sample preincubated
with TCEP/IAA was proteolytically processed to peptides corre-
sponding to loss of the N-terminal three and five amino acids
(Figure 7C).
DISCUSSION
The ribosomal origin of the lantibiotics has provided a convenient
means to conduct structure-activity relationship studies via the
generation of analogs by mutagenesis of the prepeptides.
Such mutagenesis studies have been carried out both in vivo
in the producer strains or a suitable heterologous host, and in
reconstituted in vitro systems (Chatterjee et al., 2005b; Cotter
et al., 2005; Lubelski et al., 2008). In this study, haloduracin
mutants were produced in vitro and analyzed for antibacterial
activity with a focus on the posttranslational modifications. The
outcome with the S26A mutant of HalA1 confirmed the previous
hypothesis based on sequence homology with other lantibiotics
that this residue is not dehydrated in Hala. However, the findings
with both HalA2 T18A and S22A mutants are inconsistent with
the previously proposed structure of Halb based on sequence
homology (McClerren et al., 2006). Both mutants strongly sug-
gest that Ser22 in Halb is not dehydrated, a result that was con-
firmed for wild-type HalA2 by postsource decayMS in a study on
the directionality and processivity of HalM2 (unpublished data).
The observation that the residues that escape dehydration in
both Hala and Halb are serines is in line with a previous study
that compared all known lantibiotics and concluded that Ser res-
idues escape dehydration with amuch higher frequency than Thr
residues (Rink et al., 2005). The underlying reason for this trend isChemistry & Biology 15, 1035–1not known. In the case of haloduracin, the flanking residues of
Ser26 in Hala (Pro and Cys) and Ser22 in Halb (Thr/Dhb and
Gln) are not obvious deactivating residues. For instance, a Pro
flanking Thr17 and Thr/Dhb flanking Thr2 and Thr17 in HalA2
did not negatively affect dehydration by HalM2. Although the
molecular logic of why lantibiotic synthetases sometimes skip
a Ser/Thr is not known, a potential evolutionary reason could
be that the unmodified Ser/Thr in question is important for the bi-
ological activity of the final compound. It appears, however, that
this is not the case for Ser26 in Hala and Ser22 in Halb, as shown
by antimicrobial assays of analogs in which these residues were
mutated. Similarly, the Thr17, Thr19, and Thr23 residues that re-
main unmodified in lacticin 3147 A2 (but have no homologous
residues in haloduracin) were not critical for its biological activity
(Cotter et al., 2006).
The corollary of Ser22 escaping dehydration in Halb is that
Thr18mustbedehydrated, in contrast to thehomologous residue
in lacticin 3147 A2 (Thr23), which is not dehydrated according to
NMR studies (Martin et al., 2004). The differences between these
two lantibiotics illustrate that the use of sequence homology to
predict the structure of lantibiotics is perilous. This finding is
relevant for the currently structurally uncharacterized two-com-
ponent lantibiotics Smb and BHT for which the genes were re-
cently reported. These predict 7 (BHT) or 8 (Smb) Ser/Thr in the
A-peptide and 7 Ser/Thr in the B peptide (Hyink et al., 2005;
Yonezawa and Kuramitsu, 2005) (Figure S6), but the masses
observed for the mature peptides suggest only five of these
residues are dehydrated in each peptide for Smb (Petersen
et al., 2006). The BHT/Smb peptides have sequence homology
with both haloduracin and lacticin 3147 (Figure S6), but based
on the structures of these two lantibiotics it cannot be concluded
which residues escape dehydration in Smb/BHT.
The thioether rings in lantibiotics arebelieved tobe thebasis for
their biological activity, and in general, disruption of a ring results
in abolishment of antimicrobial activity (Bierbaum et al., 1996;
Chatterjee et al., 2005b, 2006; Chen et al., 1998; Kuipers et al.,045, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1039
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SAR Studies of the Lantibiotic HaloduracinFigure 5. Representative MALDI-TOF MS Data of the HalA1-Xa or HalA2-Xa Cys-to-Ala Mutants Treated with HalM1 or HalM2
The asterisks (*) indicate phosphorylated products (Chatterjee et al., 2005a).
(A) HalA1-Xa C8A before (dashed line) and after incubation with HalM1 (solid line).
(B) HalA1-Xa C8A treated with TCEP/IAA before (dashed line) and after HalM1 (solid line).
(C) HalA2-Xa C5A before (dashed line) and after incubation with HalM2 (solid line).
(D) HalA2-Xa C5A treated with TCEP/PHMB before (dashed line) and after HalM2 treatment (solid line).1996; Ottenwa¨lder et al., 1995; van Kraaij et al., 2000). At present
only limited information is available regarding the importance of
the Lan andMeLan rings in eachpeptide of two-component lanti-
biotics. Ala scanning and random mutagenesis have been
applied to the genes encoding the precursor peptides of lacticin
3147, resulting in a large amount of valuable data (Cotter et al.,
2006; Field et al., 2007). However, the absence of bioactivity of
several of the mutants involving the thioether rings resulted
fromabolishedproductionandhenceprovidednodirect informa-
tion regarding their importance for activity. In the current study,
a comprehensive examination of the importance of each (meth-1040 Chemistry & Biology 15, 1035–1045, October 20, 2008 ª2008yl)lanthionine in haloduracin for biological activitywasperformed,
taking advantage of its in vitro reconstituted biosynthesis. These
experiments show that mutation of Cys17, Cys23, and Cys27 re-
sulted in Hala analogs in which the A, B, and C rings were disrup-
ted, respectively, without any evidence that the remaining rings
were not formed. The qualitative antimicrobial activity of these
mutants shows that the C ring of Hala is essential for activity.
Its A ring is important but not essential, with a weak zone of inhi-
bition observed, and the B ring is not required. The retention of
bioactivity upon disrupting theB ring of Halawas surprising given
its high level of conservation in comparison with mersacidinElsevier Ltd All rights reserved
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(A) Structures of Hala, lacticin 3147 A1, mersacidin, and actagardine. Residues colored green represent the proposed lipid II binding motif (CTLTXEC); the Glu
residue is blue.
(B) HalA1-Xa E22Q before (dashed line) and after incubation with HalM1 (solid line). The asterisks (*) indicate phosphorylated peptides (Chatterjee et al., 2005a).
(C) HalA1-Xa E22Q treated with TCEP/IAA before (dashed line) and after HalM1 (solid line).(C ring; Chatterjee et al., 1992), actagardine (B ring; Zimmermann
et al., 1995), and lacticin 3147 A1 (C ring; Ryan et al., 1999;
Figure 6). These three lantibiotics bind to the peptidoglycan
precursor lipid II (Bro¨tz et al., 1998;Wiedemann et al., 2006; Zim-
mermann and Jung, 1997), and the CTLTXECmotif encompass-
ing the conserved rings is believed to be important for this activ-
ity. For instance, alanine scanning mutagenesis carried out for
lacticin 3147 A1 in vivo (Cotter et al., 2006) showed this region
was highly sensitive to alterationwith respect to bioactivity. In ad-
dition, when theC ring in lacticin 3147 A1was opened, bioactivity
was abolished (Cotter et al., 2006; Field et al., 2007). At present itChemistry & Biology 15, 1035–is not knownwhydisruption of theB ring ofHala is not detrimental
to bioactivity, especially as the conserved Glu residue in the
CTLTXECmotif is critical. The abolishment of antimicrobial activ-
ity for Hala E22A and E22Q is in agreement with previous studies
on mersacidin in which the Glu was substituted with Ala and
antibiotic activity was lost (Szekat et al., 2003).
ThequalitativeSARstudies onHalb resulted in removal of itsA–
D rings. For themutants disrupting the A, C, andD rings, the rings
not targeted by mutagenesis were still formed by HalM2 accord-
ing to the PHMB data, but mutation of Cys15 resulted in disrup-
tion of cyclization for other rings in addition to the B ring. These1045, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1041
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the importance of certain residues for bioactivity on the basis of
mutagenesis studies without confirming that the mutation did
not interfere with ring formation. Based on the experimental
data, it can be concluded that the A ring in Halb is dispensable
and that theCandD ringsare important but not essential. Nocon-
clusions can be made regarding the importance of the B ring be-
cause the observed lack of bioactivity of the Halb C15A mutant
could be due to disruption of multiple rings.
This study also provides some additional insights into proteo-
lytic processing of haloduracin. Similar to the two-component
lantibiotics cytolysin and plantaricin W (Cox et al., 2005; Holo
et al., 2001), the mass of the mature Halb peptide is smaller
than that predicted by the cleavage site for the N-terminal prote-
ase domain of HalT. Additional proteolysis for cytolysin is carried
out by a designated protease, termed CylA, which was shown to
be necessary for antibiotic activity (Cox et al., 2005). No CylA ho-
mologs have been identified in theB. haloduransC-125 genome,
yet six amino acids must be removed from the N terminus of the
product that is expected to be secreted by HalT. The observed
removal of these amino acids upon exposure to the supernatant
of B. halodurans cell culture strongly suggests that one or more
secreted proteases are responsible for this process. When Hala
was first reduced, opening the disulfide ring at its N terminus,
followed by alkylation of Cys1 and Cys8 with IAA, it too became
susceptible to additional N-terminal proteolysis. Because the
disulfide is shown not to be important for antimicrobial activity
in haloduracin or in plantaricin W (Holo et al., 2001; McClerren
et al., 2006), it may be conserved to protect the peptide from
such degradation in the extracellular environment. Similarly,
the N-terminal lanthionine in lacticin 3147 A1, which is also not
required for antimicrobial activity (Cotter et al., 2006), may pro-
tect this compound from proteolyis. Interestingly, the great ma-
jority of the lantibiotics in the two-component class have cyclic
structures at or near their N termini (Figure S6).
SIGNIFICANCE
This study is the first systematic analysis of the SAR of the
individual thioether rings in a two-component lantibiotic.
Figure 7. Proteolytic Processing of Haloduracin
(A) HalA2-XaGS Q23A treated with HalM2 and Factor Xa resulted in GDVHAQ-
Halb Q23A. This peptide was used to monitor proteolytic processing.
GDVHAQ-Halb treated with supernatant of L. lactis CNRZ 117 (dashed line)
or B. halodurans C-125 (solid line). GDVHAQ-Halb Q23A calculated (calcd)
2883 Da; observed (obsd) 2886 Da. A TCEP adduct was observed at 3136
Da (Dm = 250 Da, calcd 3133 Da) and is labeled with a double asterisk (**).
Halb Q23A calcd 2276 Da; obsd 2281 Da. A TCEP adduct was observed at
2532Da (Dm=250Da, calcd 2526 Da) and is labeled with a double asterisk (**).
(B) HalA2-XaGS Q23A treated with HalM2 and then supernatant of L. lactis
CNRZ 117 (dashed line), calcd 9290 Da (M + H  7 H2O); obsd 9290 Da.
HalA2-XaGS Q23A treated with HalM2 and then supernatant of B. halodurans
C-125 (solid line), calcd 2276 Da (Halb Q23A); obsd 2279 Da.
(C) Hala isolated from B. halodurans C-125 was treated with TCEP/IAA. The
resulting bisalkylated peptide was then incubated with supernatant of L. lactis
CNRZ 117 (dashed line) or B. halodurans C-125 (solid line). Hala + 2 IAA calcd
3163 Da; obsd 3165 Da. Hala(D1–3) + IAA calcd 2745 Da; obsd 2748.
Hala(D1–5) + IAA calcd 2468 Da; obsd 2469.Elsevier Ltd All rights reserved
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Hala of haloduracin are shown to be essential for antimicro-
bial activity with wild-type Halb. The A ring of Hala is impor-
tant but not essential, and surprisingly, given its high conser-
vation in lantibiotics, the B ring is not required. The C and D
rings of Halb were important but not absolutely required for
its synergistic activity with wild-type Hala. The disulfide
ring present at the N terminus of Hala is not important for
its antimicrobial activity but protects the compound from
proteolytic degradation by proteases secreted by the pro-
ducer strain.Collectively, thesefindingsprovidenew insights
into the roles and importance of the crosslinks found in two-
component lantibiotics. This study also highlights the value
of using an in vitro biosynthetic system for SAR studies.
EXPERIMENTAL PROCEDURES
Construction of all overexpression plasmids and procedures for peptide puri-
fication are described in the Supplemental Data along with tables of all masses
of the ions observed in the mass spectra shown in this work.
Enzymatic Assays for Dehydration Activity
Purified HalA peptides were each dissolved in HalM assay buffer (50 mM Tris
[pH 8.3] for HalA1 peptides and 50 mM MOPS [pH 7.2] for HalA2 peptides) to
a final concentration of 0.3 mg/ml, and MgCl2, ATP, and TCEP were added to
final concentrations of 10 mM, 2.5 mM, and 1 mM, respectively (final volume
20 ml). Wild-type and mutant HalA1-Xa were incubated in separate reactions
with HalM1; wild-type and mutant HalA2-Xa were incubated with HalM2 with
a final enzyme concentration of 0.2 mg/ml enzyme. Activity assays were in-
cubated at 25C for 3 hr and then quenched by addition of 5% TFA to a final
concentration of 0.5% TFA and analyzed by MALDI-TOF MS. Samples were
desalted prior to MS using 10 ml C-18 ZipTip (Millipore; Billerica, MA) and
eluted with 4 ml of a-hydroxyl cinnamic acid. From this solution, 3 ml was
applied to the MALDI-TOF MS target and analyzed.
Evaluation of Cyclization Activity
For HalM1 assays, 1 ml of 100 mM iodoacetamide (IAA) was added directly to
20 ml of HalM1 assay (5 mM final concentration) and incubated at 25C for
90 min in the dark. For HalA1 starting material samples, 0.3 mg/ml peptide
was incubated in 50 mM Tris [pH 8.3] supplemented with 1 mM TCEP for
20 min prior to addition of IAA, and the reaction was carried out as described.
Samples were desalted byC-18 ZipTip (Millipore) and analyzed byMALDI-TOF
MS. For HalM2 assays, 20 ml aliquots were dried via centrivap and resus-
pended in 6 ml of 10 mM TCEP and 4 M guanidine hydrochloride [pH 8].
Samples were incubated at 25C for 20 min, 3 ml of saturated p-hydroxymer-
curibenzoic acid (PHMB) solution was added, and the reaction mixture was
incubated at 25C for 2 hr in the dark. For HalA2 starting material samples,
0.3 mg/ml peptide was dried via centrivap and PHMB assays were carried
out as described. Samples were checked for thiol modification by ZipTip
(Millipore) desalting and eluting in 4 ml of a-hydroxyl cinnamic acid to run
MALDI-TOF MS.
Antibacterial Activity Assays
Larger-scale enzymatic assays (100 ml) were carried out and then dried via
centrivap. The products were resuspended in 100 ml of Factor Xa cleavage
buffer (20 mM HEPES [pH 8.0], 100 mM NaCl, 2 mM CaCl2), and 3 ml of
1 mg/ml Factor Xa (New England Biolabs; Ipswich, MA) was added. Cleavage
reactions were incubated at 25C for 4 hr and analyzed by MALDI-TOF MS.
Samples were dried by centrivap and resuspended in 5 ml of sterile water.
Any insoluble material was removed by centrifugation at 14 krpm for 5 min in
a benchtop microcentrifuge. Solid agar diffusion assays were used to assess
bactericidal activity. An overnight culture of a haloduracin-sensitive strain,
Lactococcus lactisCNRZ 117 (Centre National de Recherches Zootechniques;
Jouy-enJosas, France), was grown in M17 medium (Difco) supplemented with
0.5% glucose at 30C under static conditions for 15–20 hr. Plates wereChemistry & Biology 15, 1035–prepared by addition of 500 ml of 20% glucose (0.5% final concentration)
and 150 ml of dense culture to 20 ml of molten M17 agar (50C) that was
then allowed to solidify in a Petri dish at 25C. Authentic haloduracin was iso-
lated from Bacillus halodurans C-125 (American Type Culture Collection) as
described previously (McClerren et al., 2006) and then further purified by
RP-HPLC to separate Hala and Halb (T. Oman and W.v.d.D., unpublished
data). For positive control samples, purified Hala and Halb peptides were
combined in a 1:1 ratio (10 ml each of 10 mM solutions). For evaluation of the
consequences of mutations, purified Hala or Halb peptides (5 ml of 10 mM so-
lution) were combined with in vitro prepared mutants (5 ml concentrated HalM
products from 100 ml-scale assays). Samples were applied to small wells that
weremanually formed in the agar plate. The seeded strain was allowed to grow
at 25C for 12 hr, and antibacterial activity was qualitatively determined by the
presence or absence of a growth inhibition zone.
Proteolytic Processing
HalA2-XaGS and HalA2-XaGS Q23A were incubated with HalM2 and treated
with Factor Xa (50 ml scale). The resulting products, GDVHAQ-Halb and
GDVHAQ-Halb Q23A, were analyzed for antimicrobial activity using solid
agar diffusion assays as described. To test if the six N-terminal amino acids
are removed by an external protease, these products were incubated with
the cell-free supernatants from B. halodurans C-125 and L. lactis CNRZ 117
cultures. B. halodurans C-125 was grown in brain heart infusion (BHI) medium
(Bacto or BBL) for 96 hr at 30C with vigorous agitation. Cultures were centri-
fuged (5000 3 g, 10 min), and cell-free supernatant was used for assays with
GDVHAQ-Halb Q23A. In addition, the cells were washed with 1 M NaCl. After
centrifugation, the cell-free 1 M NaCl wash was also used for assay with
GDVHAQ-Halb Q23A. Production of haloduracin from GDVHAQ-Halb Q23A
was analyzed by MALDI-TOF MS. Both the cell-free supernatant and the
1 M NaCl wash contained proteolytic activity as discussed in Results. L. lactis
CNRZ 117 was grown as described and its culture supernatant was used for
analogous experiments as described for B. halodurans. Identical procedures
were also used to monitor proteolytic processing of Hala and HalM2-
processed HalA2.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, and six figures and can be found with this article online
at http://www.chembiol.com/cgi/content/full/15/10/1035/DC1/.
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